STOCK TITAN

PepGen to Participate in the Stifel 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, will present at Stifel’s 2022 Annual Healthcare Conference on November 15, 2022, at 9:45 A.M. ET in New York. The presentation aims to highlight PepGen's innovative oligonucleotide therapies for severe neuromuscular and neurological diseases. A live webcast will be accessible on PepGen’s website, with a replay available for 90 days. PepGen's Enhanced Delivery Oligonucleotide (EDO) platform focuses on improving therapeutic efficacy through advanced cell-penetrating peptides.

Positive
  • None.
Negative
  • None.

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at Stifel’s 2022 Annual Healthcare Conference in New York, New York on November 15th, 2022, at 9:45 A.M. ET.

The live webcast corporate presentation may be accessed under Events and Presentations in the Investor Relations section of PepGen’s website. A replay of the webcast will be available on the website for 90 days following the presentation.

About PepGen

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are engineered to target the root cause of serious diseases. For more information, visit www.pepgen.com or follow PepGen on Twitter and LinkedIn.

Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com

Media Contact
Gwendolyn Schanker
LifeSci Communications
gschanker@lifescicomms.com


FAQ

When will PepGen present at the Stifel 2022 Annual Healthcare Conference?

PepGen will present on November 15, 2022, at 9:45 A.M. ET.

Who is presenting for PepGen at the conference?

James McArthur, Ph.D., President and CEO of PepGen, will be presenting.

Where can I watch the PepGen conference presentation?

The presentation will be available via a live webcast on PepGen’s website.

How long will the replay of the PepGen presentation be available?

A replay of the webcast will be available for 90 days following the presentation.

What is the focus of PepGen's research and development?

PepGen focuses on advancing oligonucleotide therapies for severe neuromuscular and neurological diseases.

PepGen Inc.

NASDAQ:PEPG

PEPG Rankings

PEPG Latest News

PEPG Stock Data

214.11M
32.59M
0.02%
92.49%
2.68%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON